title: A review of rilpivirine and elvitegravir resistance features and implications for treatment sequencing.
authors.forename: Amber
authors.initials: A
authors.lastname: Bourgeois
authors.forename: Samantha
authors.initials: S
authors.lastname: Womack
authors.forename: Dan
authors.initials: D
authors.lastname: Newsom
authors.forename: David
authors.initials: D
authors.lastname: Caldwell
mesh_terms: D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D009570:Nitriles / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000068696:Rilpivirine
chemical_list: D019428:HIV Integrase Inhibitors; D009570:Nitriles; D011743:Pyrimidines; D015363:Quinolones; D018894:Reverse Transcriptase Inhibitors; C509700:elvitegravir; D000068696:Rilpivirine